guest ::
| Home > Publications database > Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. > print |
| Home > Publications database > Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. > print |
| 001 | 241158 | ||
| 005 | 20240229145758.0 | ||
| 024 | 7 | _ | |a 10.3389/fimmu.2022.1096162 |2 doi |
| 024 | 7 | _ | |a pmid:36726983 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9886093 |2 pmc |
| 024 | 7 | _ | |a altmetric:141409178 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2023-00266 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Veinalde, Ruta |0 P:(DE-He78)3394ee8077921694b3249e0a5dcf355e |b 0 |e First author |
| 245 | _ | _ | |a Virotherapy combined with anti-PD-1 transiently reshapes the tumor immune environment and induces anti-tumor immunity in a preclinical PDAC model. |
| 260 | _ | _ | |a Lausanne |c 2023 |b Frontiers Media |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1675842379_14829 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a #EA:F230#LA:F230# |
| 520 | _ | _ | |a Pancreatic ductal adenocarcinoma (PDAC) is largely refractory to cancer immunotherapy with PD-1 immune checkpoint blockade (ICB). Oncolytic virotherapy has been shown to synergize with ICB. In this work, we investigated the combination of anti-PD-1 and oncolytic measles vaccine in an immunocompetent transplantable PDAC mouse model.We characterized tumor-infiltrating T cells by immunohistochemistry, flow cytometry and T cell receptor sequencing. Further, we performed gene expression profiling of tumor samples at baseline, after treatment, and when tumors progressed. Moreover, we analyzed systemic anti-tumor and anti-viral immunity.Combination treatment significantly prolonged survival compared to monotherapies. Tumor-infiltrating immune cells were increased after virotherapy. Gene expression profiling revealed a unique, but transient signature of immune activation after combination treatment. However, systemic anti-tumor immunity was induced by virotherapy and remained detectable even when tumors progressed. Anti-PD-1 treatment did not impact anti-viral immunity.Our results indicate that combined virotherapy and ICB induces anti-tumor immunity and reshapes the tumor immune environment. However, further refinement of this approach may be required to develop its full potential and achieve durable efficacy. |
| 536 | _ | _ | |a 316 - Infektionen, Entzündung und Krebs (POF4-316) |0 G:(DE-HGF)POF4-316 |c POF4-316 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a PD-1 |2 Other |
| 650 | _ | 7 | |a PDAC |2 Other |
| 650 | _ | 7 | |a cancer immunotherapy |2 Other |
| 650 | _ | 7 | |a immune checkpoint |2 Other |
| 650 | _ | 7 | |a measles vaccine |2 Other |
| 650 | _ | 7 | |a oncolytic virus |2 Other |
| 650 | _ | 2 | |a Mice |2 MeSH |
| 650 | _ | 2 | |a Animals |2 MeSH |
| 650 | _ | 2 | |a Pancreatic Neoplasms: pathology |2 MeSH |
| 650 | _ | 2 | |a Carcinoma, Pancreatic Ductal: genetics |2 MeSH |
| 650 | _ | 2 | |a Immunotherapy: methods |2 MeSH |
| 650 | _ | 2 | |a Oncolytic Virotherapy: methods |2 MeSH |
| 700 | 1 | _ | |a Pidelaserra-Martí, Gemma |0 P:(DE-HGF)0 |b 1 |e First author |
| 700 | 1 | _ | |a Moulin, Coline |b 2 |
| 700 | 1 | _ | |a Tan, Chin Leng |0 P:(DE-He78)c78afd4e9332b1120bda149010bb3633 |b 3 |u dkfz |
| 700 | 1 | _ | |a Schäfer, Theresa |0 P:(DE-He78)8c5c3b9582272e1007d788f133b43ad1 |b 4 |u dkfz |
| 700 | 1 | _ | |a Kang, Na |b 5 |
| 700 | 1 | _ | |a Ball, Claudia R |b 6 |
| 700 | 1 | _ | |a Leichsenring, Jonas |b 7 |
| 700 | 1 | _ | |a Stenzinger, Albrecht |b 8 |
| 700 | 1 | _ | |a Kaderali, Lars |b 9 |
| 700 | 1 | _ | |a Jäger, Dirk |0 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |b 10 |u dkfz |
| 700 | 1 | _ | |a Ungerechts, Guy |0 P:(DE-He78)833f90e2abdd29594ad5c4f08600f191 |b 11 |u dkfz |
| 700 | 1 | _ | |a Engeland, Christine |0 P:(DE-He78)26712fbb7710e2e6ea9de830306ce125 |b 12 |e Last author |u dkfz |
| 773 | _ | _ | |a 10.3389/fimmu.2022.1096162 |g Vol. 13, p. 1096162 |0 PERI:(DE-600)2606827-8 |p 1096162 |t Frontiers in immunology |v 13 |y 2023 |x 1664-3224 |
| 909 | C | O | |p VDB |o oai:inrepo02.dkfz.de:241158 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 0 |6 P:(DE-He78)3394ee8077921694b3249e0a5dcf355e |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-HGF)0 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 3 |6 P:(DE-He78)c78afd4e9332b1120bda149010bb3633 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 4 |6 P:(DE-He78)8c5c3b9582272e1007d788f133b43ad1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 10 |6 P:(DE-He78)ed0321409c9cde20b380ae663dbcefd1 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 11 |6 P:(DE-He78)833f90e2abdd29594ad5c4f08600f191 |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 12 |6 P:(DE-He78)26712fbb7710e2e6ea9de830306ce125 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-316 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Infektionen, Entzündung und Krebs |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-05-11T10:28:02Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-05-11T10:28:02Z |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2021-05-11T10:28:02Z |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2022-11-23 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2022-11-23 |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2022-11-23 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2022-11-23 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b FRONT IMMUNOL : 2022 |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2023-10-26 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Anonymous peer review |d 2021-05-11T10:28:02Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-10-26 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-10-26 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b FRONT IMMUNOL : 2022 |d 2023-10-26 |
| 920 | 2 | _ | |0 I:(DE-He78)F230-20160331 |k F230 |l KKE Virotherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)F230-20160331 |k F230 |l KKE Virotherapie |x 0 |
| 920 | 1 | _ | |0 I:(DE-He78)D170-20160331 |k D170 |l KKE Neuroimmunologie und Hirntumorimmunologie |x 1 |
| 920 | 1 | _ | |0 I:(DE-He78)D120-20160331 |k D120 |l D120 Angewandte Tumor-Immunität |x 2 |
| 920 | 0 | _ | |0 I:(DE-He78)F230-20160331 |k F230 |l KKE Virotherapie |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)F230-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D170-20160331 |
| 980 | _ | _ | |a I:(DE-He78)D120-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|